XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 44.71

Change

-0.22 (-0.49)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.79 (-0.54%)

USD 37.71B
FHLC Fidelity® MSCI Health Care In..

-0.43 (-0.62%)

USD 2.77B
FXH First Trust Health Care AlphaD..

-0.90 (-0.83%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.49 (-1.63%)

USD 0.20B
IDNA iShares Genomics Immunology an..

N/A

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.08 (+0.26%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-3.71 (-3.64%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.64 (-2.10%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.54 (-0.85%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.40 (-1.81%)

USD 6.67M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.03 % 0.00 %

-0.59 (-2.05%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.00% 43% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.00% 43% F 69% C-
Trailing 12 Months  
Capital Gain -1.13% 29% F 30% F
Dividend Return 1.50% 100% F 26% F
Total Return 0.37% 38% F 25% F
Trailing 5 Years  
Capital Gain -3.50% 24% F 44% F
Dividend Return 5.55% 68% D+ 15% F
Total Return 2.05% 29% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -1.90% 19% F 23% F
Dividend Return -1.13% 24% F 16% F
Total Return 0.77% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.77% 62% D 64% D
Risk Adjusted Return -7.18% 19% F 16% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.